Life Biosciences has raised $80M across 1 funding round.
Life Biosciences closed an $80 million Series D financing in April 2026 to fund its Phase 1 clinical trial of ER-100 and further development of its Partial Epigenetic Reprogramming platform.
1 funding round, the latest highlighted.
Life Biosciences was founded in 2017, United States.
No filing has been made.
1 dated round, newest first.
No. Life Biosciences is a private company; its shares do not trade on a public exchange.
The closest biotechnology / epigenetic medicines peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
